AgonOx is focused on advancing immunotherapy treatments to enhance the quality of life for cancer patients. One of their key technologies is AGX-148, which is an innovative approach to adoptive T cell therapy. This method involves the expansion and reinfusion of a patient's own tumor-infiltrating lymphocytes (TILs) to combat cancer. While TIL therapy has shown effectiveness in treating some patients with stage IV melanoma, AgonOx aims to broaden its applicability by selectively expanding tumor-reactive T cells that are specifically capable of targeting and killing tumors. This targeted approach is designed to improve the overall efficacy of TIL therapy across a wider range of cancer types.

The AGX-148 technology utilizes a streamlined process to enrich and expand these tumor-reactive T cells from the patient's own immune system. In preclinical studies, the expanded T cells have demonstrated the ability to effectively kill autologous tumor cells, as evidenced by in vitro assays. The goal of AgonOx is to refine this method further, ultimately leading to enhanced TIL therapies that can provide better outcomes for patients suffering from solid tumors. By focusing on the selective expansion of effective T cells, AgonOx is working to make significant strides in the field of cancer immunotherapy.

United States

AgonOx, Inc.is a spin-off company from the Providence Cancer Center located in Portland, Oregon. We are developing immune system activators for use in cancer therapy. Research in the field of T-cell modulation conducted worldwide with OX40 and other agents has demonstrated that the use of T-cell modulating therapies in combination with specific anti-tumor therapies have the potential for yielding therapeutic benefits for patients with cancer. AgonOx is focused on the development of immune system modulators in combination with other promising agents in the immune oncology space.

AgonOx

Company Details